In Brief: Dade International/TOA Medical Electronics
This article was originally published in The Gray Sheet
Executive SummaryDade International/TOA Medical Electronics: Ink worldwide alliance for the marketing and distribution of a combined line of hemostasis testing products. Dade will combine its line of hemostasis reagents and controls with TOA's Sysmex line of instruments. For each country where the products are sold, either Dade or TOA will "take responsibility for marketing, distribution, sales and service," Dade says. The deal is slated to go into effect on July 1 in most countries, including the U.S. and Canada, where Dade will oversee marketing. TOA's Sysmex Corp. unit will continue to directly market its hematology systems, Dade notes...
You may also be interested in...
The European Commission has set aside, for now, concerns expressed by member states regarding the scope of medicines subjected to additional monitoring requirements.
Through its partnership with majority stakeholder Nanjing King-Friend Biochemical Pharmaceutical, Meitheal Pharmaceuticals has received FDA approval for enoxaparin, a generic rival to Lovenox.
The European Commission has granted a marketing authorization for UCB and Amgen’s bone-building MAb, romosozumab, and first launches are expected in the first half of 2020; patient groups suggest that the prevention and treatment of fragility fractures has not attracted the attention it deserves.